US Edition
Dr Klempner Highlights Practice-Changing Role of Durvalumab/FLOT in Gastric Cancer
Summary by targetedonc.com
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.2 Articles
2 Articles
All
Left
Center
Right
FDA Restrictions on PD-L1-Negative Gastric Cancer Treatments
In June 2025, the US Food and Drug Administration (FDA) revised the labels for Merck’s Keytruda (pembrolizumab) and Bristol Myers Squibb’s Opdivo (nivolumab), limiting their use in advanced gastric, gastroesophageal junction (GEJ) and esophageal cancers to patients whose tumors express programmed cell death ligand 1 (PD-L1) with combined positive score ≥ 1 as determined by an FDA approved test. This decision followed a September 2024 vote by the…
Coverage Details
Total News Sources2
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
